{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination can broaden tumor antigen presentation and increase immune visibility.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Broader antigen display after intratumoral mRNA vaccination",
          "line_ref": "L28"
        },
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        }
      ],
      "caveat": "Mechanistic readouts were not uniformly strong across all tested model systems, so effect size may vary by context."
    },
    {
      "claim_id": "C02",
      "claim": "The treatment strategy induces type I interferon-associated signaling and increases PD-L1 pathway activity, supporting combination with checkpoint blockade.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors",
          "line_ref": "L31"
        },
        {
          "quote": "Interferon-associated antigen processing and presentation pathways increase.",
          "line_ref": "L43"
        },
        {
          "quote": "PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.",
          "line_ref": "L45"
        }
      ],
      "caveat": "The report emphasizes that some mechanistic readouts were strongest in specific models rather than universal across all settings."
    },
    {
      "claim_id": "C03",
      "claim": "Combination of intratumoral mRNA vaccine and anti-PD-L1 produced stronger antitumor immune signatures than controls in the preclinical murine arm.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.",
          "line_ref": "L14"
        },
        {
          "quote": "Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy",
          "line_ref": "L33"
        }
      ],
      "caveat": "Response-level details and statistical analyses for each model are not fully enumerated in the summary, limiting certainty about magnitude across tumors."
    },
    {
      "claim_id": "C04",
      "claim": "Vaccinated metastatic patients showed an associated survival advantage under ICI treatment compared with unvaccinated patients in the retrospective cohort.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "The human analysis is retrospective and non-randomized; residual confounding is likely.",
          "line_ref": "L49"
        }
      ],
      "caveat": "Because the cohort analysis is non-randomized with variable vaccination timing and treatment heterogeneity, causality cannot be inferred."
    }
  ]
}